Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 20448074)

1.

Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.

Schrier RW, Masoumi A, Elhassan E.

Clin J Am Soc Nephrol. 2010 Jun;5(6):1132-40. doi: 10.2215/CJN.01410210. Epub 2010 May 6. Review.

2.

Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.

Bauersachs J, Fraccarollo D.

Minerva Cardioangiol. 2003 Apr;51(2):155-64. Review.

PMID:
12783071
3.
5.

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

Gross E, Rothstein M, Dombek S, Juknis HI.

Am J Kidney Dis. 2005 Jul;46(1):94-101.

PMID:
15983962
6.

Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.

Tiryaki O, Usalan C, Buyukhatipoglu H.

Nephrology (Carlton). 2010 Mar;15(2):211-5. doi: 10.1111/j.1440-1797.2009.01181.x.

PMID:
20470281
7.

Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.

Dieterich HA, Wendt C, Saborowski F.

Fiziol Cheloveka. 2005 Nov-Dec;31(6):97-105. Review.

PMID:
16366159
8.

Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.

Ku E, Campese VM.

Pediatr Nephrol. 2009 Dec;24(12):2301-7. doi: 10.1007/s00467-009-1176-z. Epub 2009 Apr 4. Review.

PMID:
19347366
9.
10.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
11.

[Angiotensin II receptor blockers: current status and future prospects].

Corvol P, Plouin PF.

Drugs. 2002;62 Spec No 1:53-64. Review. French.

PMID:
12036389
12.
13.

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.

Sato A, Hayashi K, Saruta T.

Am J Hypertens. 2005 Jan;18(1):44-9.

PMID:
15691616
14.
15.

The endothelin-aldosterone axis and cardiovascular diseases.

Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC.

J Cardiovasc Pharmacol. 2001 Nov;38 Suppl 2:S49-52.

PMID:
11811378
16.

Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.

Heerspink HJ.

Adv Chronic Kidney Dis. 2011 Jul;18(4):290-9. doi: 10.1053/j.ackd.2011.04.001. Review.

PMID:
21782135
17.

Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).

Stier CT Jr, Koenig S, Lee DY, Chawla M, Frishman WH.

Heart Dis. 2003 Mar-Apr;5(2):102-18. Review.

PMID:
12713678
18.

Aldosterone and cardiovascular disease.

Gaddam KK, Pimenta E, Husain S, Calhoun DA.

Curr Probl Cardiol. 2009 Feb;34(2):51-84. doi: 10.1016/j.cpcardiol.2008.10.002. Review.

PMID:
19135616
19.

Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.

Miller AB, Srivastava P.

Cardiol Clin. 2001 May;19(2):195-202, v. Review.

PMID:
11407105
20.

Aldosterone excess or escape: Treating resistant hypertension.

Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, Sierra C, Coca A, Pimenta E, Moreno H.

J Clin Hypertens (Greenwich). 2009 May;11(5):245-52.

PMID:
19534021
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk